AbbVie Inc. (BVMF:ABBV34)

Market Cap	2.16T
Revenue (ttm)	317.87B
Net Income (ttm)	12.51B
Shares Out	n/a
EPS (ttm)	7.04
PE Ratio	172.45
Forward PE	16.82
Dividend	1.54 (2.03%)
Ex-Dividend Date	Oct 14, 2025

Volume	12
Average Volume	3,223
Open	77.46
Previous Close	76.69
Day's Range	76.01 - 77.46
52-Week Range	60.00 - 81.36
Beta	0.35
RSI	51.91
Earnings Date	Jan 30, 2026

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: ABBV34

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD